Uncorrected, long-term pulmonary regurgitation leads to right ventricular dilatation and dysfunction in a significant percentage of patients. We used magnetic resonance imaging (MRI) before and after surgery to assess the effect of pulmonary valve replacement with the Medtronic Freestyle bioprosthesis on right ventricular function and volume in nine patients with pulmonary regurgitation or stenosis. Mean follow-up time was 26 (10) months. We observed a decrease in mean end-diastolic volume from 143.6 (85.1) mL/m$^2$ to 74.1 (12.6) mL/m$^2$ ($P=0.018$) and, in end-systolic volume from 88.0 (50.3) mL/m$^2$ to 35.8 (19.3) mL/m$^2$ ($P=0.016$).

In pulmonary valve disease, extensive follow-up by MRI is essential for timely evaluation of the degree of right ventricular dilatation or dysfunction and for selecting a suitable time for valve replacement. The Medtronic Freestyle bioprosthesis is a good surgical choice for pulmonary valve replacement as its use is associated with low morbidity and mortality and the successful normalization of ventricular volumes.

Key words: Magnetic resonance imaging. Pulmonary regurgitation. Pulmonary valve. Right ventricle. Stentless prosthesis.
and/or stenosis in the Cardiac Surgery Service of Hospital Juan Canalejo, A Coruña, in northwestern Spain, between 2003 and 2005.

The demographic data were obtained from the Apollo 32 database and the review of the clinical records.

The preoperative and postoperative color Doppler and two-dimensional ultrasound images and M-mode echocardiography of all the patients were reviewed.

Right ventricular volumes and function were calculated using cardiac magnetic resonance (CMR). The maximums for right ventricular function were based on the measurements reported previously by other authors: right ventricular end-diastolic volume of ≥207 mL/m² and end-systolic volume of ≥47 mL/m², respectively, while a function ≤35% was considered to be abnormal.

Pulmonary valve replacement involved implantation of a stentless Freestyle® using a double running suture, following creation of a scallop in the noncoronary sinus to adapt it to the right ventricular outflow tract. The incision was prolonged toward the pulmonary bifurcation, and then a function ≤35% was considered to be abnormal. The main indications for pulmonary valve replacement included the presence of moderate-to-severe or severe pulmonary insufficiency in 8 patients, whereas 3 presented at least moderate-to-severe pulmonary stenosis. Five patients had an end-diastolic volume greater than 107 mL/m² and 8, an end-systolic volume greater than 47 mL/m² prior to surgery. The preoperative right ventricular ejection fraction was less than 35% in 5 patients.

Freestyle bioprostheses measuring between 23 mm and 29 mm were implanted. The mean cardiopulmonary bypass time was 82 (22) minutes.

The main follow-up period was 26 (10) months. During this period only 1 patient (no. 9) died. This patient presented tetralogy of Fallot with right ventricular dysfunction (preoperative right ventricular ejection fraction of 28%), and had been offered the possibility of heart transplantation as a first option, but refused it.

The New York Heart Association (NYHA) functional class of the patients improved from a preoperative mean of 2.5 (0.7) to 1.3 (0.7) (*P*/.015). Follow-up transthoracic echocardiography was performed 10.9 (3) months after the intervention and revealed a reduction in pulmonary valve disease in all the patients treated surgically for pulmonary insufficiency and/or stenosis (*P*/=.011 and *P*/=.016, respectively). The gradient across the prosthesis in postoperative ultrasound was 29.2 (8.6) mm Hg (interval 19-48 mm Hg).

The preoperative CMR had been carried out 9.5 (7) months prior to the intervention and was repeated 16.9 (9.4) months after surgery. The changes in right ventricular volumes are shown in Figures 1 and 2.

The mean end-diastolic volumes were reduced from 144.4 (79.6) mL/m² to 74.8 (11.8) mL/m², resulting in a mean decrease of 40% (23) (*P*/.012). The end-systolic volumes were reduced from a mean of 85.3 (47.7) mL/m²

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age at Surgery</th>
<th>NYHA Functional Class</th>
<th>Previous Surgery</th>
<th>Pre-PVR RVDV, mL/m²</th>
<th>Post-PVR RVDV, mL/m²</th>
<th>Pre-PVR RVSV, mL/m²</th>
<th>Post-PVR RVSV, mL/m²</th>
<th>Pre-PVR RVEF, %</th>
<th>Post-PVR RVEF, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>19</td>
<td>2</td>
<td>Tetralogy of Fallot</td>
<td>109.5</td>
<td>88</td>
<td>76.4</td>
<td>22.7</td>
<td>30</td>
<td>74</td>
</tr>
<tr>
<td>2</td>
<td>37</td>
<td>3</td>
<td>Ross procedure</td>
<td>93.7</td>
<td>51.5</td>
<td>72.4</td>
<td>24.3</td>
<td>22</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>23</td>
<td>3</td>
<td>Tetralogy of Fallot</td>
<td>108</td>
<td>73.1</td>
<td>76.3</td>
<td>44.6</td>
<td>29</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>1</td>
<td>Tetralogy of Fallot</td>
<td>101.2</td>
<td>79.4</td>
<td>41.7</td>
<td>22.7</td>
<td>58</td>
<td>71</td>
</tr>
<tr>
<td>5</td>
<td>13</td>
<td>2</td>
<td>Tetralogy of Fallot</td>
<td>308.9</td>
<td>65.5</td>
<td>197.2</td>
<td>24.1</td>
<td>36</td>
<td>63</td>
</tr>
<tr>
<td>6</td>
<td>29</td>
<td>3</td>
<td>Correction VSD+AVR</td>
<td>84.4</td>
<td>75.1</td>
<td>48.8</td>
<td>37.1</td>
<td>42</td>
<td>35</td>
</tr>
<tr>
<td>7</td>
<td>34</td>
<td>3</td>
<td>Pulmonary commissurotomy</td>
<td>247.7</td>
<td>86.4</td>
<td>122.8</td>
<td>75.1</td>
<td>50</td>
<td>13</td>
</tr>
<tr>
<td>8</td>
<td>16</td>
<td>3</td>
<td>Tetralogy of Fallot</td>
<td>150.7</td>
<td>79.4</td>
<td>63.9</td>
<td>22.8</td>
<td>31</td>
<td>71</td>
</tr>
<tr>
<td>9</td>
<td>51</td>
<td>3</td>
<td>Tetralogy of Fallot</td>
<td>95.7</td>
<td>Not available</td>
<td>Not available</td>
<td>Not available</td>
<td>Not available</td>
<td>Not available</td>
</tr>
</tbody>
</table>

*AVR indicates aortic valve replacement; NYHA, New York Heart Association; PVR, pulmonary valve replacement; RVDV, right ventricular diastolic volume; RVEF, right ventricular ejection fraction; RVSV, right ventricular systolic volume; VSD, ventricular septal defect.

RESULTS

The demographic and clinical data and the results of magnetic resonance studies are shown in the Table.

The main indications for pulmonary valve replacement were the presence of moderate-to-severe or severe pulmonary insufficiency in 8 patients, whereas 3 presented at least moderate-to-severe pulmonary stenosis. Five patients had an end-diastolic volume greater than 107 mL/m² and 8, an end-systolic volume greater than 47 mL/m² prior to surgery. The preoperative right ventricular ejection fraction was less than 35% in 5 patients.

Freestyle bioprostheses measuring between 23 mm and 29 mm were implanted. The mean cardiopulmonary bypass time was 82 (22) minutes.

The mean follow-up period was 26 (10) months. During this period only 1 patient (no. 9) died. This patient presented tetralogy of Fallot with right ventricular dysfunction (preoperative right ventricular ejection fraction of 28%), and had been offered the possibility of heart transplantation as a first option, but refused it.

The New York Heart Association (NYHA) functional class of the patients improved from a preoperative mean of 2.5 (0.7) to 1.3 (0.7) (*P*/.015). Follow-up transthoracic echocardiography was performed 10.9 (3) months after the intervention and revealed a reduction in pulmonary valve disease in all the patients treated surgically for pulmonary insufficiency and/or stenosis (*P*/=.011 and *P*/=.016, respectively). The gradient across the prosthesis in postoperative ultrasound was 29.2 (8.6) mm Hg (interval 19-48 mm Hg).

The preoperative CMR had been carried out 9.5 (7) months prior to the intervention and was repeated 16.9 (9.4) months after surgery. The changes in right ventricular volumes are shown in Figures 1 and 2.

The mean end-diastolic volumes were reduced from 144.4 (79.6) mL/m² to 74.8 (11.8) mL/m², resulting in a mean decrease of 40% (23) (*P*/.012). The end-systolic volumes were reduced from a mean of 85.3 (47.7) mL/m²

REV ESP CARDIOL. 2007;60(6):656-9 657
to 34.2 (18.4) mL/m², that is, a mean decrease of 54% (P=.012). The overall mean right ventricular ejection fraction increased following valve replacement, although the increase was not statistically significant (from 36% [11] to 54% [20]; P=.09).

After valve replacement, the normalization of the end-diastolic volume was observed in all 9 patients (<107 mL/m², whereas the end-systolic volume was restored to normal in 8 (<47 mL/m²).

Correlation analysis of the preoperative right ventricular end-diastolic volume and the percent reduction in this volume showed that the latter was greater in patients with greater preoperative volumes (r=0.78; P=.021) (Figure 3).

**DISCUSSION**

Vliegen et al² demonstrated that pulmonary valve replacement produced substantial improvements in hemodynamic and ventricular function in patients with pulmonary insufficiency and right ventricular dilation. However, the improvement in ventricular function following pulmonary valve replacement clearly depends on the timing of the intervention. When valve replacement is carried out at the proper time, echocardiography reveals a reduction of the diameters of the right chambers and an improvement in right ventricular contractility.³⁻⁵ Other studies report different results with regard to the changes in right ventricle after pulmonary valve replacement when measured by means of echocardiography.³⁻⁵ The irregular shape of right ventricle and unpredictable way in which it dilates complicate its quantitative analysis, either using echocardiography or catheterization.

Cardiac magnetic resonance offers clear advantages over echocardiography and ventriculography since it does not rely on geometric approximations for the calculation of right ventricular mass, volumes, and function, while it enables a better assessment of possible akinetic zones and/or aneurysmal disease in the right ventricular outflow tract.

Pulmonary valve replacement carries little risk in patients with pulmonary insufficiency, with a perioperative mortality of 1% to 4% ³ and a mean 10-year survival of 95%,⁴ when it is not associated with some other surgical procedure. In all of our patients, the postoperative morbidity and mortality were 0, and remained so after a maximum follow-up of 26 (10) months.

At the present time, there is a wide and varied range of prosthetic options for pulmonary valve replacement. However, to date, there is no “ideal” replacement for the native pulmonary valve.

We have observed that the greater the right ventricular end-diastolic volume at the time of surgery, the greater
the percent reduction in this parameter following valve replacement. This finding differs with respect to the results reported by other authors, who affirm that beyond a certain right ventricular volume, the decrease is minimal.\textsuperscript{1} We consider that these positive results may be due to the use of a stentless prosthesis since, in the first place, these prostheses are associated with excellent hemodynamic results when implanted in the pulmonary position, better than those observed with stented prostheses, and, according to some studies, better than those achieved with homografts. However, it should be pointed out that, to date, no prosthesis has been found to be the ideal replacement for the pulmonary valve and that both the stentless porcine prostheses and homografts are excellent options for the treatment diseases of the right ventricular outflow tract.

The importance of pulmonary valve disease should not be underestimated. It requires exhaustive follow-up with CMR to determine the degree of right ventricular dilation and dysfunction as early as possible. This enables us to decide on the best moment for pulmonary valve replacement and, later, to evaluate the outcome of the surgery.

The results obtained in our study with respect to the restoration of right ventricular geometry and the clinical improvement of the patients are very encouraging, and are similar to those reported recently by other authors.\textsuperscript{1,2}

REFERENCES